渣打集团(02888)有意首次退出少数业务 以增加对富裕客户业务的投资Shangao New Energy (01250) plans to receive a cash withdrawal offer from Shankao Holdings (00412) at a premium of about 7.23%; Standard Chartered Group (02888) intends to withdraw from a small number of businesses for the first time to increase investment in the business of wealthy customers
[Important matters]
Shangao New Energy (01250) plans to receive a cash withdrawal offer from Shangao Holdings (00412) at a premium of about 7.23%
Standard Chartered Group (02888) intends to withdraw from a few businesses for the first time to increase investment in the business of wealthy customers
Hanson Pharmaceuticals (03692): The fifth marketing license application for amelox (ametinib mesylate tablets) was accepted by the China Drug Administration
Columbotai Bio-B (06990): The core product Lucan Satuzumab (Sac-TMT) was approved by the State Drug Administration for marketing based on Optitrop-Breast01 to treat line 2 and above TNBC
China Biopharmaceutical (01177): Bemosubizumab injection combined with anlotinib hydrochloride capsules for the treatment of endometrial cancer approved for marketing
Kangzhe Pharmaceutical (00867): Innovative drug GLP-1R/GCGR dual agonist CMS-D005 received approval notice for drug clinical trials
[Bonds and notes]
Anta Sports (02020) proposes to issue 1.5 billion euro zero-interest guaranteed convertible bonds due in 2029
[Buy/Increase or Decrease Holds]
CSPC Group (01093) spent HK$29.60714 million to buy back 5.82 million shares on November 27
China Petroleum & Chemical Co., Ltd. (00386) spent HK$25.7472 million to buy back 6.204 million shares on November 27
AIA (01299) spent HK$0.447 billion to buy back 7.761 million shares on November 27
Tencent Holdings (00700) spent HK$0.704 billion to buy back 1.77 million shares on November 27
For more details, please refer to Zhitong Financial Network ()
